Acadia Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Acadia Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Acadia Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Acadia Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Acadia Pharmaceuticals Inc (Acadia) is a biopharmaceutical company focused on the research, development, and commercialization of treatments for conditions such as parkinson’s disease psychosis (PDP), alzheimer’s disease psychosis (ADP), Prader-Willi syndrome (PWS), and Rett syndrome. Acadia's major products include NUPLAZID (pimavanserin) and DAYBUE (trofinetide) to treat specific central nervous system (CNS) disorders. The company's products are used by neurologists, psychiatrists, and long-term care physicians to treat PDP patients globally. Acadia collaborates with other pharmaceutical companies to advance its research and development efforts. The company operates facilities in San Diego, California, and Princeton, New Jersey, in the US. Acadia is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
12830 El Camino Real, Suite 400, San Diego, California, 92130
Website
www.acadia.com
Telephone
1 858 5582871
No of Employees
796
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ACAD (NASD)
Revenue (2024)
$1.1B
11.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
72.7%
(2024 vs 2023)
Market Cap*
$4.3B
Net Profit Margin (2024)
XYZ
54.4%
(2024 vs 2023)
* As of and is in US$
Acadia Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pimavanserin: To treat hallucinations and delusions associated with Parkinson’s Disease Psychosis | DAYBUE |
| Trofinetide: To treat Rett Syndrome | NUPLAZID |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Divestiture | In December, the company sold its Rare Pediatric Disease Priority Review Voucher for US$150 million. |
| 2024 | Contracts/Agreements | In November, the company received a global license from Saniona to create and commercialize SAN711 for essential tremors. |
| 2024 | Asset Purchase | In October, the company acquired three opioid treatment program clinics in South Carolina, the US. |
Competitor Comparison
| Key Parameters | Acadia Pharmaceuticals Inc | Otsuka Pharmaceutical Co Ltd | Eisai Inc | Taysha Gene Therapies Inc | Allergan Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Japan | United States of America | United States of America | Ireland |
| City | San Diego | Chiyoda-Ku | Nutley | Dallas | Dublin |
| State/Province | California | Tokyo | New Jersey | Texas | Leinster |
| No. of Employees | 796 | 6,070 | 832 | 99 | - |
| Entity Type | Public | Private | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stephen R. Biggar, MD, PhD | Chairman | Executive Board | 2016 | 55 |
| Catherine Owen Adams | Chief Executive Officer; Director | Executive Board | 2024 | 55 |
| Mark C. Schneyer | Chief Financial Officer; Executive Vice President | Senior Management | 2021 | 52 |
| Konstantina Katcheves | Chief Business Officer; Chief Strategy Officer | Senior Management | 2025 | - |
| Jennifer J. Rhodes | Chief Legal Officer; Secretary; Executive Vice President | Senior Management | 2024 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer